文献速递鼻科

冷冻疗法治疗慢性鼻炎:前瞻性多中心注册研究长期结果

Cryotherapy as Treatment for Chronic Rhinitis: Long-Term Results of a Prospective, Multicenter Registry.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-10-07

该前瞻性多中心注册研究纳入354例接受ClariFix冷冻治疗的成人慢性鼻炎患者,共932次治疗,随访24个月。结果显示鼻症状总分和生存质量持续改善,超过73%为应答者,无器械或治疗相关严重不良事件。

要点

  • 冷冻疗法可显著改善慢性鼻炎患者鼻部症状和生活质量,疗效持续至24个月。
  • 器械或治疗相关不良事件均为短暂、非严重,通常经非处方药和温热饮品缓解。

核心结论

  • 该注册研究进一步证实冷冻疗法治疗慢性鼻炎在多样人群中至24个月的安全性和有效性。

研究设计与样本

  • 前瞻性、多中心、非随机、观察性注册研究,共纳入354例接受ClariFix冷冻治疗的成人过敏性/非过敏性慢性鼻炎患者,共932次治疗。

主要发现

  • 从基线至所有随访,反射性鼻症状总分平均变化显著(P < .001);超过73%的参与者在所有随访中达到≥1分改善(应答者)。
  • 基线反射性鼻症状总分≥7分的参与者改善程度大于<7分者(P < .001)。
  • 超过74%的参与者在所有随访中达到生存质量应答(小鼻结膜炎生存质量问卷评分≥0.4分)。
  • 超过73%的参与者在所有随访中报告患者总体印象变化改善;临床医生在3个月随访时注意到87.1%的参与者有改善。
  • 未报告器械或治疗相关严重不良事件;器械和治疗相关不良事件为短暂、非严重,通常经非处方药和温热饮品缓解。

临床怎么用

  • 对于成人过敏性/非过敏性慢性鼻炎,ClariFix冷冻疗法可作为改善鼻部症状和生活质量的选择,且安全性良好至24个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this registry was to capture observational data on a large and diverse cohort treated with the ClariFix Cryotherapy device for chronic rhinitis. STUDY DESIGN: Prospective, multicenter, nonrandomized, observational registry. SETTING: Twenty-two tertiary care and private otolaryngology practices. METHODS: ClariFix treatment was administered to adult patients with allergic or nonallergic chronic rhinitis. Outcome measures included the reflective Total Nasal Symptom Score, mini Rhinoconjunctivitis Quality of Life Questionnaire, Patient Global Impression of Change, Clinician Global Impression-Improvement, and adverse events related to the device or procedure through 24-month follow-up. RESULTS: A total of 354 participants received 932 treatments. The mean change in total reflective Total Nasal Symptom Score from baseline to all follow-ups was significant (P < .001); greater than 73% of participants were responders, achieving ≥1 point reduction at all follow-ups. Participants with baseline reflective Total Nasal Symptom scores ≥ 7 had greater improvement than those with baseline scores < 7 (P < .001). Greater than 74% of participants were quality of life responders (≥0.4 points) at all follow-ups with the mini Rhinoconjunctivitis Quality of Life Questionnaire. More than 73% of participants reported PGIC improvement at all follow-ups. Clinicians noted improvement in 87.1% of participants at 3-month follow-up. No device- or treatment-related serious adverse events were reported. Device- and treatment-related adverse events were transient, nonserious, and typically resolved by over-the-counter medication and warm beverages. CONCLUSION: This registry provides additional long-term evidence of the safety and efficacy of cryotherapy for the treatment of chronic rhinitis in a diverse population through 24 months.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Luong AU, Mehendale NH, Szabo E, et al. Cryotherapy as Treatment for Chronic Rhinitis: Long-Term Results of a Prospective, Multicenter Registry. Otolaryngol Head Neck Surg. 2026. PMID: 42841538. doi:10.1002/ohn.70470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。